Bergen, Norway, 7 November 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, is pleased to announce it has been accepted for a poster presentation at the 61st Annual American Society of Hematology (ASH) Meeting, which takes place from 7-10 December 2019 in Orlando, Florida. … Read more
Bergen, Norway, 7 November 2019 – BerGenBio ASA (OSE:BGBIO), will announce its results for the third quarter on Tuesday 19 November 2019. A presentation by BerGenBio’s senior management team will take place at 10am CET at: Arctic SecuritiesHaakon VIIs gate 5Oslo The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Financial … Read more
Primary endpoint, Overall Response Rate, has been met in predominantly PD-L1 negative/low patients Secondary endpoint, median Progression Free Survival, exceeds expectations in AXL positive patients Data to be presented at Society for Immunotherapy of Cancer 34th Annual Meeting on 8 November 2019 Bergen, Norway, 6 November 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company … Read more
Bergen, Norway 22nd October 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, today announces that the U.S. Food and Drug Administration (FDA) has approved Fast Track Designation for bemcentinib for the treatment of elderly patients with acute myeloid leukaemia (AML) whose disease has relapsed. There … Read more
Bergen, Norway, 02 October 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, is pleased to announce it has been accepted for an oral presentation at the Society for Immunotherapy of Cancer (SITC)’s 34th Annual Meeting, which is being held from 6-10 November 2019 in … Read more
Bergen, Norway, 27 September 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, is to provide study updates in two poster presentations from its Phase II clinical development programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, at the European Society for Medical … Read more
Bergen, Norway, September 10 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces today that Richard Godfrey, BergenBio’s chief executive officer, will present at the H.C. Wainwright 21st Annual Global Life Sciences Conference today, September 10, 2019. Date: Tuesday, September 10, 2019Time: 5.15pm CESTLocation: Lotte New … Read more
Bergen, Norway, 8 September 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will present study updates from its Phase II clinical development programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, in non-small cell lung cancer (NSCLC) at the 2019 World Conference … Read more
Bergen, Norway, 3 September 2019 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 28 August 2019 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise options pursuant to the … Read more
Bergen, Norway, 2 September 2019. BerGenBio ASA (the”Company”) (OSE: BGBIO). Reference is made to the stock exchange notice dated 28 August 2019 and primary insiders exercise of share options which expire in 2019. Primary Insider Richard Godfrey (CEO) exercised 225,000 options equal to 225,000 shares. To cover costs related to the exercise, Richard Godfrey transferred … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.